More evidence has showed that in anti‐PD‐1/PD‐L1 monotherapy, the response rates which are typically around 25% and can be as low as 5% in immune‐deserted (or immunologically “cold”) tumors, such as uveal melanoma, where T cells are almost completely inattentive to the tumor.78, 79, 80. The gene discussed is CD274; the disease is uveal melanoma.